美沙拉嗪联合双歧杆菌三联活菌治疗轻-中度溃疡性结肠炎的临床疗效及其安全性

Clinical efficacy and safety of mesalazine combined with bifidobacterium triple viable in the treatment of mild to moderate ulcerative colitis

目的探讨美沙拉嗪联合双歧杆菌三联活菌治疗轻-中度溃疡性结肠炎(UC)的临床疗效及其安全性。方法选取大田县总医院消化内科2017年1月—2020年1月收治的轻-中度UC患者80例,随机分为对照组与观察组,每组40例。对照组给予美沙拉嗪肠溶片治疗,观察组在对照组基础上加用双歧杆菌三联活菌治疗。比较2组临床疗效,治疗前后C反应蛋白(CRP)水平、红细胞沉降率(ESR)、临床症状评分、改良Mayo评分、Baron内镜评分、疾病活动指数(DAI)评分,并比较2组不良反应发生率。结果观察组总有效率高于对照组(P<0.05)。治疗前2组CRP、ESR、临床症状评分比较,差异无统计学意义(P>0.05);治疗后观察组CRP、ESR、临床症状评分低于对照组(P<0.01)。治疗前2组改良Mayo评分、Baron内镜评分、DAI评分比较,差异无统计学意义(P>0.05);治疗后观察组改良Mayo评分、Baron内镜评分、DAI评分低于对照组(P<0.01)。观察组不良反应发生率低于对照组(P<0.05)。结论美沙拉嗪联合双歧杆菌三联活菌治疗轻-中度UC的临床疗效确切,可改善临床症状,降低炎性反应,控制病情活动,促进肠道黏膜愈合,且安全性较高.

Objective To investigate the clinical efficacy and safety of mesalazine combined with Bifidobacterium triple viable in the treatment of mild to moderate ulcerative colitis(UC).Methods A total of 80 cases of patients with mild to moderate UC were selected from January 2017 to January 2020 in the General Hospital of Datian,which were randomly divided into control group and observation group,40 cases in each group.The control group was treated with mesalazine enteric coated tablets,and the observation group was treated with Bifidobacterium triple viable on the basis of the control group.The clinical efficacy,C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),clinical symptom score,modified Mayo score,Baron endoscopic score and disease activity index(DAI)score were compared between the two groups before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).There was no significant difference in CRP,ESR and clinical symptom scores between the two groups before treatment(P>0.05),after treatment,CRP,ESR and clinical symptom scores of the observation group were lower than those of the control group(P<0.01).Before treatment,there was no significant difference in modified Mayo score,Baron endoscopic score and DAI score between the two groups(P>0.05);after treatment,the modified Mayo score,Baron endoscopic score and DAI score of the observation group were lower than those of the control group(P<0.01).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Mesalazine combined with Bifidobacterium triple viable has definite clinical efficacy in the treatment of mild to moderate UC,which can reduce inflammatory reaction,improve clinical symptoms,reduce modified Mayo score,Baron endoscopic score,DAI,and with high safety.